A Phase 2/3 Adaptive Double-blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Adult and Pediatric subjects With APOL1-mediated Proteinuric Kidney Disease

Go Back to All Clinical Trials

A Phase 2/3 Adaptive Double-blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Adult and Pediatric subjects With APOL1-mediated Proteinuric Kidney Disease

Brief description of study

This is an adaptive Phase 2/3 study of VX-147 in subjects Adult and Pediatric with APOL1-mediated proteinuric kidney disease that is designed to select a dose of VX-147 and establish the efficacy and safety of the selected dose

Clinical Study Identifier: s22-01371

ClinicalTrials.gov Identifier: NCT05312879

Principal Investigator: David Michael Charytan.

Other Investigators: David T Liu, Nina J Caplin.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies